Mayne Pharma launches Lexette foam
Mayne Pharma is introducing Lexette (halobetasol propionate) foam 0.05%.
The product, which was previously approved by the Food and Drug Administration, is a new formulation of halobetasol, a potent topical corticosteroid indicated for the treatment of plaque psoriasis in adult patients.
Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed, according to the company.
"Lexette is an elegant foam formulation that will give psoriasis patients more treatment options. The foam delivery platform has a well-established reputation with dermatologists due to ease of application and lack of greasiness and stickiness, especially in hair-bearing areas and under clothing,” Mayne CEO Scott Richards said.
The product, which was previously approved by the Food and Drug Administration, is a new formulation of halobetasol, a potent topical corticosteroid indicated for the treatment of plaque psoriasis in adult patients.
Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed, according to the company.
"Lexette is an elegant foam formulation that will give psoriasis patients more treatment options. The foam delivery platform has a well-established reputation with dermatologists due to ease of application and lack of greasiness and stickiness, especially in hair-bearing areas and under clothing,” Mayne CEO Scott Richards said.